Lumos Diagnostics Holdings (ASX:LDX) and Hologic agreed to expand the scope of work for the new fetal fibronectin test, according to a Monday Australian bourse filing.
The expanded scope of work relates to phase 3 of the development agreement, which focuses on delivery of the system prototype and will include the incorporation of additional hardware features into the proprietary reader technology.
This is expected to generate additional fee revenue for Lumos of between $600,000 to $800,000.
Phase 2 of the development agreement is expected to complete around April. The phase seeks to demonstrate that the assay can detect a biomarker.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。